182 related articles for article (PubMed ID: 11421251)
1. Muscarinic agonists and antagonists in the treatment of Alzheimer's disease.
Greenlee W; Clader J; Asberom T; McCombie S; Ford J; Guzik H; Kozlowski J; Li S; Liu C; Lowe D; Vice S; Zhao H; Zhou G; Billard W; Binch H; Crosby R; Duffy R; Lachowicz J; Coffin V; Watkins R; Ruperto V; Strader C; Taylor L; Cox K
Farmaco; 2001 Apr; 56(4):247-50. PubMed ID: 11421251
[TBL] [Abstract][Full Text] [Related]
2. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease.
Clader JW; Wang Y
Curr Pharm Des; 2005; 11(26):3353-61. PubMed ID: 16250841
[TBL] [Abstract][Full Text] [Related]
3. On the physiological relevance of muscarinic acetylcholine receptors in Alzheimer's disease.
Koch HJ; Haas S; Jürgens T
Curr Med Chem; 2005; 12(24):2915-21. PubMed ID: 16305479
[TBL] [Abstract][Full Text] [Related]
4. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.
Fisher A
Neurotherapeutics; 2008 Jul; 5(3):433-42. PubMed ID: 18625455
[TBL] [Abstract][Full Text] [Related]
5. Facilitation of acetylcholine release and improvement in cognition by a selective M2 muscarinic antagonist, SCH 72788.
Lachowicz JE; Duffy RA; Ruperto V; Kozlowski J; Zhou G; Clader J; Billard W; Binch H; Crosby G; Cohen-Williams M; Strader CD; Coffin V
Life Sci; 2001 Apr; 68(22-23):2585-92. PubMed ID: 11392630
[TBL] [Abstract][Full Text] [Related]
6. SCH 57790: a novel M2 receptor selective antagonist.
Lachowicz JE; Lowe D; Duffy RA; Ruperto V; Taylor LA; Guzik H; Brown J; Berger JG; Tice M; McQuade R; Kozlowski J; Clader J; Strader CD; Murgolo N
Life Sci; 1999; 64(6-7):535-9. PubMed ID: 10069520
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.
Fisher A
Jpn J Pharmacol; 2000 Oct; 84(2):101-12. PubMed ID: 11128032
[TBL] [Abstract][Full Text] [Related]
8. New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.
Greig NH; Reale M; Tata AM
Recent Pat CNS Drug Discov; 2013 Aug; 8(2):123-41. PubMed ID: 23597304
[TBL] [Abstract][Full Text] [Related]
9. [Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer's disease or inappropriate tactics?].
Vamvakidès A
Ann Pharm Fr; 2003 May; 61(3):207-10. PubMed ID: 12714934
[TBL] [Abstract][Full Text] [Related]
10. M
Russell JK; Ingram SM; Teal LB; Lindsley CW; Jones CK
ACS Chem Neurosci; 2023 Feb; 14(3):435-457. PubMed ID: 36655909
[TBL] [Abstract][Full Text] [Related]
11. Potential role of muscarinic agonists in Alzheimer's disease.
Avery EE; Baker LD; Asthana S
Drugs Aging; 1997 Dec; 11(6):450-9. PubMed ID: 9413702
[TBL] [Abstract][Full Text] [Related]
12. The utility of muscarinic agonists in the treatment of Alzheimer's disease.
Messer WS
J Mol Neurosci; 2002; 19(1-2):187-93. PubMed ID: 12212779
[TBL] [Abstract][Full Text] [Related]
13. Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors.
Messer WS; Rajeswaran WG; Cao Y; Zhang HJ; el-Assadi AA; Dockery C; Liske J; O'Brien J; Williams FE; Huang XP; Wroblewski ME; Nagy PI; Peseckis SM
Pharm Acta Helv; 2000 Mar; 74(2-3):135-40. PubMed ID: 10812950
[TBL] [Abstract][Full Text] [Related]
14. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update.
Fisher A
Curr Alzheimer Res; 2007 Dec; 4(5):577-80. PubMed ID: 18220527
[TBL] [Abstract][Full Text] [Related]
15. Towards a high-affinity allosteric enhancer at muscarinic M1 receptors.
Lazareno S; Popham A; Birdsall NJ
J Mol Neurosci; 2002; 19(1-2):123-7. PubMed ID: 12212769
[TBL] [Abstract][Full Text] [Related]
16. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.
Fisher A; Brandeis R; Bar-Ner RH; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z
J Mol Neurosci; 2002; 19(1-2):145-53. PubMed ID: 12212772
[TBL] [Abstract][Full Text] [Related]
17. The optimization of a novel selective antagonist for human M
Li M; Huang C; Wu X; Ding F; Hu Z; Zhu Y; Zhao L; Hou L; Chen H; Wang H; Xu J; Tang D
Bioorg Med Chem Lett; 2020 Dec; 30(24):127632. PubMed ID: 33132116
[TBL] [Abstract][Full Text] [Related]
18. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.
Verma S; Kumar A; Tripathi T; Kumar A
J Pharm Pharmacol; 2018 Aug; 70(8):985-993. PubMed ID: 29663387
[TBL] [Abstract][Full Text] [Related]
19. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
Scarpa M; Hesse S; Bradley SJ
Adv Pharmacol; 2020; 88():277-310. PubMed ID: 32416870
[TBL] [Abstract][Full Text] [Related]
20. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives.
Fisher A; Michaelson DM; Brandeis R; Haring R; Chapman S; Pittel Z
Ann N Y Acad Sci; 2000; 920():315-20. PubMed ID: 11193170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
